Podcasts about Shulgin

Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families.   Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u

Matt Xavier is a full-time psychedelic guide, DJ, and mental health counselor whose remarkable career has spanned more than three decades at the intersection of music, healing, and expanded states of consciousness. In the early 1990s, Matt gained prominence as “Matthew Magic,” a pioneering force in New York City's underground electronic music scene. As cofounder of Tsunami Productions, he introduced Psychedelic Trance to the North American East Coast and later founded the influential techno label Railyard Recordings. Throughout his tenure, he held DJ residencies in both New York and Los Angeles, performing at renowned festivals and clubs around the world. Educated at Loyola Marymount University and credentialed in California, Matt has worked as a certified Gestalt therapist and co-occurring addiction counselor, providing evidence-based care at leading treatment centers across Los Angeles. In 2019, he received formal training in psychedelic-assisted therapy and launched Integrated Psychedelics—a private practice offering harm-reduction therapy, integration counseling, and immersive, music-enhanced psychedelic journeys. Through his work with Therapeutic DJing, Matt teaches others how to harness the powerful synergy between music and psilocybin-assisted therapy to support emotional release, healing, and deep personal transformation. Career News: Book release Early June 2025:  The Psychedelic DJ - A Practical Guide to Therapeutic Music Curation and Psilocybin-Assisted Therapy DJ Sets @ Psychedelic Science Conference June 2025: Shulgin 100 Year Birthday Celebration @ Psychedelic Science 2025 - Denver, feat. Oona Dahl & Matt Xavier AFTERGLOW: unofficial ambient-techno afterhours for Psychedelic Science 2025 - Denver, feat. Oona Dahl & Matt Xavier Matt's Links Mr. Bill's Links

In episode 14 of Psychedelic Divas, my guest is Wendy Tucker, daughter of psychedelic pioneer Ann Shulgin, who was married to ground-breaking psychedelic chemist Sasha Shulgin. Wendy shares her extensive history within the psychedelic community, including hosting the infamous Friday Night Dinners that began as a family gathering and evolved into a critical hub for underground psychedelic culture. Wendy discusses Ann and Sasha's legendary work, including Sasha's resynthesis of MDMA along with 200 novel compounds and Ann's seminal therapeutic contributions within the psychedelic community. Wendy also discusses the creation of the Shulgin Foundation, whose goal is to preserve the historic Shulgin Farm and lab, and the ongoing community efforts to maintain this legacy. The conversation touches on Sasha's meticulous process for testing novel compounds, the importance of safe and informed psychedelic use, and the educational work being continued today through the Foundation and other platforms. This episode offers a deep dive into the historical and personal stories that shaped the psychedelic movement.   Learn More About the Shulgins To find out about events at the Shulgin Farm or to contribute to the foundation, go to: ShulginFoundation.org   To order PIHKAL or TIHKAL or other books, check out TransformPress.com   Rent the movies: Dirty Pictures and Better Living Through Chemistry on streaming platforms or view on YouTube   Find the Shulgin Vault at Erowid.org   Connect with Carla If you're inspired by this episode and want to stay connected, follow Carla and Psychedelic Divas on social media or visit the website to get your Psychedelic Safety Guide Including What to Do When Things Go Wrong: ·        Website: PsychedelicDivas.com ·        Carla's Coaching: CarlaDetchon.com ·        Instagram: @psychedelicdivas ·        YouTube: @carladetchon ·        Subscribe & Review: If you enjoyed this episode, please subscribe, rate, and review Psychedelic Divas. Your support helps amplify these important conversations and grow our community.

La protagonista della puntata numero 7 è una sostanza illecita destinata a liberarsi dallo stigma dell'immoralità che le aleggia intorno da 40 anni. Una sostanza popolarissima che ha molti soprannomi. In origine era Adam, poi Ecstasy, Molly, XTC, X, o MD. Qualcuno si è spinto a definirla la “penicillina dell'anima”, per noi sarà sempre e solo MDMA. Testo, voce e editing audio: Stefania BonanLetture e contributi liberamente tratti da:“PIHKAL, a chemical love story” di Alexander e Ann Shulgin. Transform Press, Berkeley California 2022. Traduzione di SB“Through the gateway of the heart - Accounts of experiences with MDMA and other empathogenic substances” a cura di Sophia Adamson. Four Trees Publications, San Francisco 1985. Traduzione di SB.“Pursuit of ecstasy, the MDMA experience” di Jerome Beck e Marsha Rosenbaum. State University of New York Press, Albany, 1994 Traduzione di SB. Frammenti interpretati da DV.“The history of MDMA” di Torsten Passie. Oxford University Press, Oxford 2023. Traduzione di SB . Frammenti interpretati da DV.Comunicazioni dirette interpretate da DV.Da aporee.org:Different birds, dove, wind on leaves content_copy P.André • 04.06.2024 12:00 Europe/Lisbon • 1:36min. • PUBLIC-DOMAIN Mining bees - small colony burrowing into gravel track content_copy Peter Cusack • 18.07.2024 14:58 Europe/London • 6:53min. • PUBLIC-DOMAINSolar farm at day break - the hum, wood pigeon song, close chattering song thrush, distant crows and gulls content_copy Peter Cusack • 28.07.2024 05:51 Europe/London • 8:45min. • PUBLIC-DOMAINIl ringraziamento per il supporto va a OEJ Agency, Portogruaro - Italia.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/sostanze--5350496/support.

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Wendy Tucker, board chair of Shulgin Farm and owner of Transform Press. Find full show notes and links here: https://thethirdwave.co/podcast/episode-282-wendy-tucker/?ref=278 Wendy shares intimate stories about her stepfather Alexander "Sasha" Shulgin and mother Ann, including their remarkable love story and groundbreaking work in psychedelic research. She discusses the historic significance of the Shulgin Farm, where Sasha's famous lab produced over 200 novel compounds, and details current efforts to preserve this important piece of psychedelic history. The conversation explores the Shulgins' legacy of open science, collaborative research, and their impact on the current psychedelic renaissance. Highlights: History of Shulgin Farm and its significance since 1935  The love story of Sasha and Ann Shulgin MDMA, 2-CB, and a litmus test of lovemaking The Shulgins' legacy of bold research and open science The longterm vision of the Farm and Shulgin Foundation Wendy's initial impressions of Sasha Sasha's methodical approach to creating and testing new compounds The 1994 DEA raid and its impact Transform Press and the story of PiHKAL & TiHKAL Current preservation efforts and fundraising goals Links: Shulgin Farm Transform Press Instagram: @shulginfoundation Episode Sponsor: The Practitioner Certification Program by Third Wave's Psychedelic Coaching Institute.

In this episode, we explore the rapidly evolving landscape of psychedelics, examining recent legal milestones like Dr. Joe Tafur's victory in Arizona for the use of Ayahuasca as a religious sacrament, as well as the União do Vegetal's (UDV) landmark Supreme Court case nearly two decades ago. These developments signal a broader trend in the U.S. toward decriminalization and legalization, with states such as Oregon and Colorado leading the way in establishing regulated frameworks for psilocybin services. We also delve into the nuances of psychedelic use across therapeutic, ceremonial, and recreational settings, emphasizing the importance of proper set and setting, especially for first-time users. Through personal stories, we illustrate how even challenging experiences in therapeutic contexts can lead to profound transformation. Additionally, we trace the history from setbacks in the 1980s, when MDMA was classified as a Schedule I substance, to the resurgence of research in the 2000s, highlighting the expanding acceptance of psychedelics for healing and mental health. Show notes: ●      Psychedelics shifted from ceremonial to personal use ●      Shulgin synthesized new psychedelics, including MDMA ●      MDMA research resurgence ●      Ceremonial integrity relies on properly trained guides ●      Therapy versus ceremonial approaches versus recreation ●      Psychedelic therapy requires a comprehensive, supportive framework ●      Ensuring proper support for first-timers How you can help others in a big way...  If you enjoy the Higher Practice Podcast, please leave a quick review on the Apple Podcast app. It makes a big difference in getting the word out to other people who will benefit from this podcast. Simply, click on the show on your podcast app>scroll down to the bottom of the episodes>click the ratings and reviews section>tap stars to rate>click write a review. To learn more, visit: https://psychiatryinstitute.com/  Interested in providing psychedelic therapy? Download our free ebook, Getting Started With Psychedelic Therapy: https://bit.ly/3NjBW9k Struggle with mental health? Download our free guide, 10 Must Know Supplements For Optimal Mental Health: https://bit.ly/4feDMob.  And when you download our free guide, you'll also get our bi-weekly newsletter Mind Matters, where we share great tips on how to optimize your mental health.

Welcome to a special edition of Alternatief.TV. The Netherlands is on Ukrainian side participating in a war between Russia and Ukraine. Our mainstream media is giving a very one-sided pro-Ukrainian and anti-Russian view on the conflict. It is crucial for a peace-settlement to have a dialogue with Russia and listen to the arguments from the other side. After the 24 february 2022, I had two exclusive interviews with the former Russian ambassador to the Netherlands, Mr. Shulgin. The new Russian Ambassador to the Netherlands is Mr. Tarabrin.Welkom bij een speciale editie van Alternatief.TV. Nederland staat aan de kant van Oekraïne en neemt deel aan de oorlog tussen Rusland en Oekraïne. Onze mainstream media geeft een zeer eenzijdige pro-Oekraïense en anti-Russische kijk op het conflict. Voor een vreedzame oplossing is het essentieel om in dialoog te gaan met Rusland en naar de argumenten van de andere kant te luisteren. Na 24 februari 2022 heb ik twee exclusieve interviews gehad met de voormalige Russische ambassadeur in Nederland, de heer Shulgin. De nieuwe Russische ambassadeur in Nederland is de heer Tarabrin.---Café Weltschmerz gelooft in de kracht van het gesprek en zendt interviews uit over actuele maatschappelijke thema's. Wij bieden een hoogwaardig alternatief voor de mainstream media. Café Weltschmerz is onafhankelijk en niet verbonden aan politieke, religieuze of commerciële partijen.Waardeer je onze video's? Help ons in de strijd naar een eerlijker Nederland, vrij van censuur en Steun Café Weltschmerz en word Stamgast!https://www.cafeweltschmerz.nl/maandelijks-doneren/Wil je meer video's bekijken en op de hoogte blijven via onze nieuwsbrief? Ga dan naar: https://www.cafeweltschmerz.nl/videos/Wil je op de hoogte worden gebracht van onze nieuwe video's? Klik hierboven dan op Abonneren!

Arpita is back with another story in the series on psychedelics. MDMA has an interesting history, but could it have a future in mental health treatment as well? For more information and sources for this episode, visit https://www.smartteapodcast.com.

In this episode, Joe interviews Keeper Trout: archivist, author, photographer, co-founder of the Cactus Conservation Institute, and creator of Trout's Notes, a website compiling personal research and collected data to help ethnobotanical researchers. From an interest in cactus taxonomy, Sasha Shulgin urged Trout to go through his files, resulting in a friendship, and eventually, an 8-year project of digitizing all of these files into the ever-evolving Shulgin Archive. Trout discusses: His relationship with Sasha and The Shulgin Farm project, which aims to make the farm a community resource for therapy, research, events, and more The messiness of cactus taxonomy, and how he believes we're nearing the end of being able to properly identify plants The perception of LSD as unnatural and why the natural vs. synthetic argument is largely political Why repealing the Controlled Substances Act is the path we should take over decriminalization or legalization and more! For links and more, head to the show notes page. 

In this episode, released on Ann Shulgin's birthday, Joe interviews Wendy Tucker: Daughter of Ann and Stepdaughter to Alexander “Sasha” Shulgin. Recorded in Sasha's old office, she recounts her formative years, giving an insider's look into her Mother's openness about psychedelics, working with Sasha in the lab, how the Shulgins made a perfect team, and watching a close-knit circle of self-experimenters start to form at Shulgin Farm – and keep coming back over the years. She talks about the energy infused into the property from the decades of research and gatherings, and how she is trying to preserve it – not just to capture its history and the pioneering research that happened there, but as a beacon for future generations. She imagines weddings, conferences, other communal gatherings, and more. Imagine taking a chemistry course in Sasha Shulgin's lab? To learn more about the project and to donate, head to Shulginfarm.org. Click here to head to the show notes page and watch the video.

In one final episode for 2023 / season 4 of Curiosity Killed the Rat, Kade and Matt bring you an extended special reflecting on one of the biggest Australian milestones of 2023: the re-classification and approval of MDMA and Psilocybin to assist therapy. Kade leads us through the science accompanying the historical journey of these drugs; from their discovery and synthesis, through their recreational use (both legal and illegal), to their status today as promising therapeutic compounds. Stick around for a listener question of great seriousness and importance: If a tree in the forest falls and no one is there to hear it, does it make a sound? As always, you can find us @curiosityrat on X, instagram, and facebook, and send your listener questions in to curiosityrat@gmail.com We also have a Patreon! If you love our content and want to support us you can jump on to https://www.patreon.com/curiosityrat and become a patron. There is absolutely ZERO pressure but if you have as little as $1/month you can chuck it our way to help us out and show you appreciate all the time and effort that goes into making this show. References: Kade's Article The Therapeutic Odyssey of Psilocybin and MDMA: A Return to Roots https://rsv.org.au/psilocybin-and-mdma/ Seeking the magic mushroom — Originally published in 1957 Life Magazine https://www.trippingly.net/lsd/2018/5/14/seeking-the-magic-mushroom Hofmann, A. (1959). Psychotomimetic drugs. Acta physiologica et pharmacologica Neerlandica, 8, 240-258. Shulgin, A. T. (1964). 3-Methoxy-4 5-methylenedioxy Amphetamine, a New Psychotomimetic Agent. Nature, 201(4924), 1120-1121. Stolaroff, M. J. (1997). The secret chief revealed: Conversations with a pioneer of the underground psychedelic therapy movement. Multidisciplinary Association for Psychedelic Studies (MAPS). Sessa, B., Higbed, L., & Nutt, D. (2019). A review of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Frontiers in psychiatry, 10, 138. Nutt, D. J., King, L. A., & Nichols, D. E. (2013). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience, 14(8), 577-585. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry, 68(1), 71-78. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of±3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of psychopharmacology, 25(4), 439-452. Li, N. X., Hu, Y. R., Chen, W. N., & Zhang, B. (2022). Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. Journal of Affective Disorders, 296, 26-34. Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., ... & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402-1411. Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., ... & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA psychiatry, 79(10), 953-962. Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse, 43(1), 55-60. Peck, S. K., Shao, S., Gruen, T., Yang, K., Babakanian, A., Trim, J., ... & Kaye, W. H. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nature Medicine, 29(8), 1947-1953. Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., ... & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137-3148. Wolfson, P. E., Andries, J., Feduccia, A. A., Jerome, L., Wang, J. B., Williams, E., ... & Doblin, R. (2020). MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Scientific reports, 10(1), 20442. Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., ... & Doblin, R. (2023). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Focus, 21(3), 315-328. Nicholas, C. R., Wang, J. B., Coker, A., Mitchell, J. M., Klaire, S. S., Yazar-Klosinski, B., ... & Doblin, R. (2022). The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug and alcohol dependence, 233, 109356. Sessa, B., Higbed, L., O'Brien, S., Durant, C., Sakal, C., Titheradge, D., ... & Nutt, D. J. (2021). First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of Psychopharmacology, 35(4), 375-383. Hoshi, R., Bisla, J., & Curran, H. V. (2004). The acute and sub-acute effects of ‘ecstasy'(MDMA) on processing of facial expressions: preliminary findings. Drug and Alcohol Dependence, 76(3), 297-304. Rootman, J. M., Kiraga, M., Kryskow, P., Harvey, K., Stamets, P., Santos-Brault, E., ... & Walsh, Z. (2022). Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Scientific Reports, 12(1), 11091. Cavanna, F., Muller, S., de la Fuente, L. A., Zamberlan, F., Palmucci, M., Janeckova, L., ... & Tagliazucchi, E. (2022). Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Translational Psychiatry, 12(1), 307. Passie, Torsten, and Andrew Dennis, 'The Early History of MDMA', The History of MDMA MAPS FDA MDMA application: https://mapsbcorp.com/news/mdma-for-ptsd-fda-submission/ MDMA neurotoxicity: https://www.science.org/doi/10.1126/science.301.5639.1479b https://www.science.org/doi/10.1126/science.1074501 https://www.science.org/doi/10.1126/science.301.5639.1454b https://www.ncbi.nlm.nih.gov/pmc/articles/PMC194116/ Woke pharmaceuticals: https://wokeph.com/ Tik Tok Video: https://vt.tiktok.com/ZSNCVW7gn/

Slothrop is reborn as "Rocketman," steals some hash, and meets Mickey Rooney, The John E. Badass appears, and does battle using a hot new drug named Oneirine Thiophosphate (or is it Theo-phosphate???). This episode: we talk with documentarian and chemist Hamilton Morris about the novel's use of drugs, and chemistry, both technically and metaphorically. Is Oneirine real? Could it be?! Other topics include: The BoDeans, William S. Burroughs, Alexander "Sasha" Shulgin, alternate histories and uchronies, the feeling of an elf sitting on your chest, S&M sex (again), chemophobia, plasticity, and the weak, pitiable nature of the covalent bond. Read ⁠Proverbs For Paranoids,⁠ John's guide to Gravity's Rainbow. Read "(Unfinished) Review of PIHKAL: A Chemical Love Story" attributed to one "Tyrone Slothrop." E-mail us your questions, queries, and crackpot theories: slowlearnerspod@gmail.com

Buon venerdì Stupefan! Prima di iniziare a raccontarvi del nuovo e inestimabile "how to regulate" della Transform Drug Policy Foundation, dedicato agli psichedelici, ci siamo resi conto che manca all'appello una monografica: la DMT! Probabilmente è la triptamina più nota al mondo, questa molecola ha una storia millenaria che si perde nell'alba dei tempi, mentre invece la sua sintesi arriva nell'ultimo secolo e ci ha permesso di capire quanto sia capillarmente diffusa all'interno gli esseri viventi ed endemica a piante, animali e umani. Per capirla ci avvarremo delle esperienze degli scienziati che l'hanno studiata e proveremo ad immaginarci universi paralleli fatti di colori ed entità sconosciute. La DMT è una sostanza psicoattiva che pretende molto, molto rispetto ed insieme conosceremo le sue molte forme, i metodi per assumerla, i rischi nell'utilizzarla, i safer use per consumarla e tante altre informazioni che ci permetteranno di conoscerla meglio. Ora è il momento di cliccare play. Note dell'episodio:- Cos'è la DMT (danno.ch): https://danno.ch/sostanze/dmt-5-meo-dmt-Come agiscono le triptamine: https://www.stateofmind.it/2018/11/triptamine-dmt/- Un estratto da Pharmaco Gnosis di Dale Pendell: https://not.neroeditions.com/dale-pendell-farmaco-gnosi-dmt/- Terence McKenna, Il cibo degli dei: https://www.amazon.it/nutrimento-degli-dei-Terence-McKenna/dp/889371079X- Il Tihkal: https://www.amazon.it/Tihkal-Continuation-Alexander-Shulgin/dp/0963009699Entra in contatto con noi usando la mail stupefatticast@gmail.como seguendo su Instagram il @stupefatti_podcast!Puoi anche iscriverti a STUPEGRAM, il nostro canale telegram, a questo link https://t.me/stupegram!

Alexander Theodore "Sasha" Shulgin (June 17, 1925 – June 2, 2014) was an American medicinal chemist, biochemist, organic chemist, pharmacologist, psychopharmacologist, and author. He is credited with introducing 3,4-methylenedioxymethamphetamine (MDMA, commonly known as "ecstasy") to psychologists in the late 1970s for psychopharmaceutical use and for the discovery, synthesis and personal bioassay of over 230 psychoactive compounds for their psychedelic and entactogenic potential. In 1991 and 1997, he and his wife Ann Shulgin compiled the books PiHKAL and TiHKAL (standing for Phenethylamines and Tryptamines I Have Known And Loved), from notebooks that extensively described their work and personal experiences with these two classes of psychoactive drugs. Shulgin performed seminal work into the descriptive synthesis of many of these compounds. Some of Shulgin's noteworthy discoveries include compounds of the 2C* family (such as 2C-B) and compounds of the DOx family (such as DOM). Due in part to Shulgin's extensive work in the field of psychedelic research and the rational drug design of psychedelic drugs, he has since been dubbed the "godfather of psychedelics". Original videos ⁠⁠here and here Full Wikipedia entry ⁠⁠here⁠⁠ Sasha Shulgin's books ⁠⁠here --- Support this podcast: https://podcasters.spotify.com/pod/show/theunadulteratedintellect/support

An dem Podium mit dem Titel „Was ist Bewusstseinserweiterung? Pioniere der Forschung berichten über eigenen Erfahrungen“ nahmen teil: Richard Baker-Roshi, Betty G. Eisner, Roland Fischer, Felicitas D. Goodman, Albert Hofmann, Hanscarl Leuner, Ralph Metzner und Alexander T. Shulgin. Moderation: Gero von Boehm und Rolf Verres. Dieses lebendige und lehrreiche Gespräch aus dem Jahre 1996 ist ein einzigartiges und durchaus auch ein hoch aktuelles Dokument. Die Beforschung der Möglichkeiten (und zu berücksichtigenden Risiken), die in der Verwendung bewusstseinsverändernder Substanzen wie Psilocybin liegt, gewinnt seit einiger Zeit wieder enorm an Aufmerksamkeit. Alle Folgen der "Autobahnuniversität" finden Sie auch hier: www.carl-auer.de/magazin/autobahnuniversitat Die anderen Podcasts des Carl-Auer Verlags finden Sie hier: Heidelberger Systemische Interviews www.carl-auer.de/magazin/heidelberger-systemische-interviews Sounds of Science www.carl-auer.de/magazin/sounds-of-science sich-sicher-sein www.carl-auer.de/magazin/sich-sicher-sein

For access to the full Sus Psychedelics, Inc. series and other premium episodes, subscribe to the Al-Wara' Frequency at patreon.com/subliminaljihad. PHASE THREE: RUNNING THE SHOW Dimitri's high school experiences with 2C-B and MDMA, the synchronicity of the Hyphy/Thizz movement sprouting up in Alexander Shulgin's East Bay backyard, the extremely different vibes around drugs in 2005, Dimitri's 2009 documentary about suburban Thizz dealers in the Bay… The origins of the Multidisciplinary Association for Pyschedelic Studies (MAPS), “Early Therapeutic Use of MDMA, 1977-1985”, the Boston Group, Shulgin turning on Lt. Colonel Leo Zeff aka “The Secret Chief” to MDMA in 1977, ARUPA at Esalen, Jungian lay therapist Ann Shulgin, her theory that using MDMA helps you recognize the positive aspects of the totally selfish demon inside you, Chilean Dr. Claudio Naranjo and Sasha Shulgin's collaboration from 1962 onward, Jack Downing's Exuma Island Institute in the Bahamas, Dr. George Greer and his wife Requa Tolbert, Catholic priest Michael Clegg who began selling ecstasy in Dallas night clubs in 1983, Dr. Rick Ingrasci promoting MDMA therapy on Donahue in 1985, Tim Leary's former Harvard research partner Ralph Metzner, Doblin founding the Earth Metabolic Design Laboratories (EMDL) in 1984, Physical Abuse in MDMA-Assisted Psychotherapy, founding MAPS advisors Francesco Di Leo and Rick Ingrasci both losing their therapist licenses for having sex with patients during MDMA sessions… Background on Psychedelic godfather Alexander “Sasha” Shulgin, Shulgin's decades-long relationship with the DEA, his membership at Bohemian Grove, Shulgin's infamous bad vibes concoction STP/DOM, German pharma companies selling 2C-B aka “Nexus” in 1990s South Africa, PHASE FOUR: DIMITRI'S TRIP Dimitri reveals for the first time his journeys with “Gustavo”, a Peruvian shaman to the 0.01% in 2011, getting psyopped by ayahuasca utopianism, and which billionaires were secretly getting EnLiGhTeNeD years before the new corporadelic renaissance hit the mainstream.

This week: drugs! Psychedelic drugs and the man responsible for inventing most of them, Alexander Shulgin. Shulgin was a "psychopharmacologist" who, due to a special arrangement with the DEA, invented, synthesized, and tested on himself and his friends, hundreds of brand-spankin'-new psychedelic drugs, many of which are referred to now as "research chemicals. Alexander Shulgin is also known as the "godfather of ecstasy" for his role in re-discovering MDMA and became a counterculture hero after the publication of his books PiHKAL and TiHKAL, which provided detailed recipes and analyses for over 200 different substances as well as an absolutely insufferable love story. Also he was a member of the Bohemian Club (the one with the grove), and a pretty odd fellow in general.    Support The Nonsense Bazaar on Patreon and get access to our bonus series The Corkboard Bizarre and join the community over at our new patron-only Discord server for $5 a month! https://patreon.com/thenonsensebazaar

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss MDMA-assisted therapy. They explore the following topics: (2:00) Making this year the best year yet(3:57) The early  history of MDMA with Alexander "Sasha" Shulgin and Merck (7:00) The pioneering work of Sasha and Ann Shulgin(9:32) Why MDMA became illegal and the repercussions (10:23) MDMA study with couples(11:00) Chemical structure and mechanisms of action in the brain(13:20) Why does MDMA help with PTSD and post-traumatic growth(19:40) Is MDMA the same as ecstasy or molly?(21:10) Harm reduction, drug testing, and dosages (22:35) The desirable and undesirable effects of MDMA(25:20) Can MDMA kill you?(27:10) Interactions with other drugs(33:00) The MDMA come-down and how people try to compensate for it(36:28) MAPS MDMA therapy training(38:24) Principle components of the MDMA experience(40:54) Ann Shulgin's 4 agreements before beginning MDMA therapy(45:24) Oxytocin (46:37) Critical periods of development Email us questions and feedback at psychfrontiers@novamind.ca Learn more about our podcast at https://www.psychedelictherapyfrontiers.com/Learn more about Numinus at https://www.numinus.com/Follow us on Instagram: https://www.instagram.com/drstevethayer/https://www.instagram.com/innerspacedoctor/https://www.instagram.com/numinushealth/Disclaimer: The content of this podcast does not constitute medical advice or mental health treatment. Consult with a medical/mental health professional if you believe you are in need of mental health treatment.

Prosegue il viaggio stupefacente nella Summer Edition 2022 di Stupefatti.Seguendo il "filo rosso" tracciato dal nuovissimo documentario Netflix, intitolato "Come cambiare la tua Mente", oggi raccontiamo la vita e le imprese di Alexander "Sasha" Shulgin, chimico, biochimico e farmacologo statunitense famoso per avere riscoperto l'MDMA, ma che nella sua lunga vita professionale ha ideato e sintetizzato oltre duecento molecole psichedeliche dalle incredibili proprietà terapeutiche. Armatevi di ghiacciolo e schiacciate play!Note dell'episodio: - Il documentario Netflix "Come cambiare la tua Mente": https://bit.ly/3oTXi0X- Acquista il libro di A. Shulgin "Pihkal: a Chemical love story": https://amzn.to/3vPvZZu- Acquista il libro di Albert Hofmann "LSD: il mio bambino difficile": https://amzn.to/3AdNOEo- Acquista il libro di Pollan da cui è tratto il documentario: https://amzn.to/3vF6CK1Entra in contatto con noi usando la mail stupefatticast@gmail.com o seguendo su Instagram il @stupefatti_podcast!

Dr. Jon and Brian take a break from kratom to look at the recently released Netflix documentary series hosted by Michael Pollan, How to Change Your Mind. In related good news: the DEA backed off its decision to schedule five psychedelics. Hamilton Morris tweets. “Today the DEA withdrew their plan to prohibit DiPT, 4-HO-DiPT, 5-MeO-MiPT, … Journal Club #34: How to Change Your Mind Documentary Read More » The post Journal Club #34: How to Change Your Mind Documentary first appeared on Kratom Science.

John Wilson on Tony Sirico, the former armed robber turned actor who found fame playing the role of mobster Paulie Walnuts in ground-breaking television series The Sopranos. José Eduardo dos Santos, who ruled Angola as president for 37 years, steering the country through a bloody civil war, and reaping the benefits of an oil boom while being accused of huge levels of corruption. Ann Shulgin, a therapist who pioneered the use of psychedelics and MDMA in therapy together with her chemist husband Sasha. And Ivana Trump, the Czechoslovakian skier and model whose marriage to Donald Trump made her a fixture of tabloid and society pages for decades. Producer: Tim Bano Interviewed guest: Fr Robert Sirico Interviewed guest: Dr Justin Pearce Interviewed guest: Amanda Feilding Interviewed guest: Professor David Nutt Archive clips used: Paramount Pictures, The First Wives Club (1996); American Playhouse, The Big Bang (1989); NBC Today, 20th Anniversary of 'The Sopranos' 10/01/2019; HBO, The Sopranos (1999); Miramax/ Sweetland Films/ Magnolia Production, Bullets Over Broadway (1994); YouTube, Comício José Eduardo dos Santos - Angola 1992 16/09/2010; BBC Sound Archive, Independence celebrations in Angola 11/11/1975; BBC Radio 4, News 23/02/2002; BBC News Archive, Angola vote in first election for 16 years 05/09/2008; BBC Two, Panorama - The Corrupt Billionaire 25/01/2020; Viveka Films, MDMA The Movie - Promo Clip (2016); CBS News, When Ecstasy was legal 1985; gaiamedia/ YouTube channel, Ask the Shulgins 17/03/2014; BBC One, Wogan - Ivana Trump interview 03/06/1992; CBS Sunday Morning, Ivana Trump interview 08/10/2017; BBC Radio 4, Woman's Hour - Ivana Trump interview 03/06/1992; HBO/ Harpo Productions, The Oprah Winfrey Show 25/04/1998; BBC One, Modern Times - The Fame Game 03/01/1996; Del Monte/ Brian Jackson, UK Del Monte pears advert (2014).

https://blogs.berkeley.edu/2022/07/11/ann-shulgin-radiant-nexus-of-psychedelic-community/ https://www.marijuanamoment.net/dea-announces-hearing-on-proposed-ban-of-five-psychedelic-compounds-following-significant-pushback/ https://www.marijuanamoment.net/dea-may-find-itself-in-federal-court-again-over-refusal-to-provide-psilocybin-access-to-terminally-ill-patients/ https://www.westword.com/news/michael-floorwax-defends-ketamine-but-not-in-elijah-mcclain-case-11922627 https://kdvr.com/video/paramedics-disciplined-for-ketamine-violations/7818750/

Abby and Robbie dive deeper into the life and work of Sasha and Anne Shulgin and their close yet tumultuous relationship with the DEA, their books PiHKAL / TiHKAL , the raid of his home and the crackdown on “designer drug” internet retailers that were selling pure chemical drugs following the recipies from both of Shulgin's books. This is Episode 6 of an ongoing series on Psychedelic History, Episodes 1-6 are availible now. Patreon subscribers at the $5 tier get access to Episode 4 of the series: www.patreon.com/mediarootsradio Previous: Episode 1: A Brief History of Hallucinogens, MK-Ultra, the CIA, LSD, Leary & the Psychedelic 60s / 70s Episode 2: How Raves Brought Back the Psychedelic Subculture, DanceSafe, Pill Tests & the DEA vs MDMA Episode 3: Terrence McKenna, Johnathan Ott, DMT, Pharmahuasca, Heroic Dosing, Utopianism & the Psychedelic New Age Episode 4: When Microsoft Employee #9 Boosted an Online Psychedelic Revolution, Erowid.org, DXM & Salvia Episode 5: the Acid Drought, Making DMT, A Godfather of Psychedelic Analogs & His Problem Child 2-C-T-7 FOLLOW // twitter.com/AbbyMartin // twitter.com/FluorescentGrey //

In this episode, Brynn Anderson and I take a peek into the psychedelic life of master chemist Alexander 'Sasha' Shulgin, creator of over 250 psychedelic compounds such as 2C-I and 2C-B...We listen to some incredible interviews from both 1996 and 2013, just prior to Sasha's death. We discuss how his many psychedelic compounds have influenced humanity ,as Shulgin was on a quest to be a toolmaker for psychedelic research. Listen In!Alexander Shulgin Bio:Dr. Alexander "Sasha" Theodore Shulgin or "Shura" was an American chemist, pharmacologist, psychopharmacologist, and author.Over the span of 50 years, he created more new psychedelic drugs than any other known person to date - nearly 250 by his own accounts.Shulgin also rediscovered the drug MDMA and established its use as a tool in clinical psychedelic therapy for a short time. He has written two books detailing his endeavors, PiHKAL and TiHKAL, and also contributed numerous highly appraised chemical assays and studies throughout the years.Shulgin is best known for synthesizing the psychoactive drugs 2C-T-7, 2C-B, 2C-E, 2C-I, DOM and hundreds of others. Due in part to Shulgin's extensive work in the field of psychedelic research and the rational drug design of psychedelic drugs, he has since been dubbed the "godfather of psychedelics". Prior to his 2010 health issues, Shulgin had been working on a series of N- allylated tryptamines including 5-MeO-DALT and 5-MeO-MALT On April 17, 2014, Ann Shulgin reported on Facebook that her husband had developed liver cancer, and in a May 31 update on Facebook she said that, although appearing frail, he seemed to be experiencing his last moments in peace and without pain. On June 2, 2014, Shulgin died at home in bed surrounded by family, fifteen days before his 89th birthday Get bonus content on Patreon See acast.com/privacy for privacy and opt-out information.

Cosa sono i trip report? Perché in certi casi arrivano a costituire una sorta di genere letterario? A cosa serve il sito Erowid? Chi era Alexander Shulgin e cosa c'entra con tutto questo? Ne parliamo nella diciottesima puntata di Illuminismo psichedelico, insieme allo scrittore e sceneggiatore Peppe Fiore, che in “La scommessa psichedelica” (Quodlibet) ha scritto un saggio intitolato “Il trip report come sottogenere della letteratura di viaggio”.

Nick talks to medicinal chemist Dr. David Nichols, who has spent decades studying the chemistry and pharmacology of psychedelics. Dr. Nichols shared his knowledge of psychedelic tryptamine, including LSD and DMT, as well as phenethylamines such as mescaline and MDMA. He also discussed his relationship with the late Dr. Alexander "Sasha" Shulgin, and how his thoughts companies trying to make non-hallucinogenic drugs derived from psychedelics.USEFUL LINKS:Download the podcast & follow Nick at his website[www.nickjikomes.com]Support the show on Patreon & get early access to episodes[https://www.patreon.com/nickjikomes]Sign up for the weekly Mind & Matter newsletter[https://mindandmatter.substack.com/]Athletic Greens, comprehensive daily nutrition (Free 1-year supply of Vitamin D w/ purchase)[https://www.athleticgreens.com/mindandmatter]Try MUD/WTR, a mushroom-based coffee alternative[https://www.mudwtr.com/mindmatter]Discount Code ($5 off) = MINDMATTEROrganize your digital highlights & notes w/ Readwise (2 months free w/ subscription)[https://readwise.io/nickjikomes/]Start your own podcast (get $20 Amazon gift card after signup)[https://www.buzzsprout.com/?referrer_id=1507198]Buy Mind & Matter T-Shirts[https://www.etsy.com/shop/OURMIND?ref=simple-shop-header-name&listing_id=1036758072§ion_id=34648633]Connect with Nick Jikomes on Twitter[https://twitter.com/trikomes]​​​Learn more about our podcast sponsor, Dosist[https://dosist.com/]ABOUT Nick Jikomes:Nick is a neuroscientist and podcast host. He is currently Director of Science & Innovation at Leafly, a technology startup in the legal cannabis industry. He received a Ph.D. in Neuroscience from Harvard University and a B.S. in Genetics from the University of Wisconsin-Madison.Support the show (https://www.patreon.com/nickjikomes)

“ I have these epiphanies all the time, especially if I had anchovies on my pizza..” Could the White Helmets be involved in staging chemical attacks? When James Le Mesurier fell to his death in Turkey in 2019 he left behind a tangle of truths and lies. Mayday tells the extraordinary real story of the man who organised the White Helmets – rescuers who film themselves pulling survivors from bombed out buildings in rebel-held areas of Syria – and investigates claims that, far from being heroes, they are part of a very elaborate hoax. James Le Mesurier – his detractors say – was a British secret agent, pulling the strings. So when his body was found by worshippers on their way to morning prayers, there were a lot questions. Produced, written and presented by: Chloe Hadjimatheou Editor: Emma Rippon Researcher: Tom Wright Mixed by: Neil Churchill Arabic translation and additional research: Vanessa Bowles, Abdul Kader Habak Turkish researcher: Nevin Sungur Narrative Consultant: John Yorke Original music: Nick Mundy and Bu Kolthoum Production Coordinator - Gemma AshmanREFERENCES “Roger Waters - Reporting The Truth” Roger Waters YouTube channel, 6 December 2019 “Briefing by Chief of Main Operational Directorate of Russian General Staff Sergei Rudskoy” Минобороны России (Ministry of Defense of Russia) YouTube channel 17 March 2018“Voices of people hiding in a basement in #EasternGhouta while #Assad regime & #Russia forces shell the area. Trying to destroy #Syria & kills its people or make them succumb to starvation & tyranny.” Dima Moussa @dimam78 Tweet 04 March 2018Syria Gas Attack Victims Treated at Hospital, Syria Civil Defence video“Russia's Foreign Minister Sergey Lavrov - BBC HARDtalk rushes” - BBC HARDtalk exclusive, 17 April 2018برومو رجل الثورة Revolution Man promotional video, 10 February 2018 - Movie Produced by the Syrian ministry of culture“Gasping for life: Syria's merciless war on its own children” CNN كونتاك الحلقة 23 Panet46 (Contac Episode 23 Panet46) dailymotion - Shoof Drama شوف دراما“Ethics Forum: Paul McKeigue (Edinburgh Usher Institute)” 25 January 2019 video from Jamie Smith on 12 February 2019, published on the University of Edinburgh website“UN: Chlorine was placed in Douma by militants for provocative purposes –Russia's OPCW rep. Shulgin” 20 January 2020, Ruptly YouTube Channel (Ruptly is part of the same media family as RT) credit: UNIFEED-UNTV

Ecstasy, MDMA, Molly...whatever name you know it by Alexander 'Sasha' Shulgin is the man behind it all. A brilliant chemist who dedicated his life to the research of psychedelic drugs. This 2010 doc directed by Etienne Sauret profiles the life of the man who brought MDMA to the mainstream. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/threedudespod/message

Once upon a time there was a scientist who was introduced to a drug that made him feel wondered, made him feel complete, and knew that this drug could help many people all over the world. Soon, however, the government decided that no one should have this drug, not even scientist or doctors. In response the scientist told everyone who wanted to know, how to make it themselves. Today I have the story of a remarkable man named Alexander Shulgin on the 189th episode of Sunday Morning Coffee with Jeff. Show notes and links: * Dirty Pictures (2010 Documentary, 720p HD) (youtube.com) * Alexander Shulgin – Wikipedia (wikipedia.org) * MDMA Healing I AM REBEL THE LOVE DRUG S01E03 alexander sacha shulgin Documentary (youtube.com) * Dr. Ecstasy – The New York Times (nytimes.com) * Shulgin was known to many as the “Godfather of ecstasy” | NZ Drug Foundation (drugfoundation.org.nz) * Ann and Sasha Shulgin – Pihkal and Tihkal: A Chemical Love Story (youtube.com) * My Lunch with Psychedelic Chemist “Sasha” Shulgin (RIP) and His Wonderful Wife (scientificamerican.com)

Download In this episode, Kyle hosts a conversation with Veronika Gold from the Polaris Insight Center, a center that offers Ketamine Assisted Psychotherapy. They compare and contrast Ketamine Psychotherapy methods and Ketamine Infusion. 3 Key Points: The most studied way of using Ketamine has been infusion, mainly used for treatment resistant depression and PTSD. Veronika used lozenges and intramuscular Ketamine therapy working for Polaris. When people are healed from depression, there is a lot of anxiety and activation that happens. Infusion clinics don't offer the therapeutic help that comes with Ketamine Assisted Psychotherapy. The dissociation that happens with Ketamine is a different dissociation that happens with trauma. With trauma, dissociation happens when the nervous system can't handle the stress in someone's life, with Ketamine, it allows people who feel dissociated from their trauma, to feel again. Support the show Patreon Leave us a review on iTunes Share us with your friends – favorite podcast, etc Join our Facebook group - Psychedelics Today group – Find the others and create community. Navigating Psychedelics Trip Journal                                                Integration Workbook             Show Notes About Veronika She specialized in trauma treatment She is involved in the clinical trials for the treatment of PTSD, sponsored by MAPS in San Francisco Veronika is originally from Czech Republic She studied at CIIS She grew up in the Czech Republic in a communist time so she dealt with a lot of trauma She met Stan Grof at 16 at a Transpersonal conference She was fascinated with his work and Transpersonal Breathwork became a part of her healing It lead her to study psychology and become a psychotherapist and study non-ordinary states Ketamine Assisted Psychotherapy Ketamine therapy has been studied from the late 60’s until today The most studied way of using Ketamine has been infusion, mainly used for treatment resistant depression and PTSD In Ketamine Assisted Psychotherapy, the therapy is as important as the medicine There is a biochemical effect of Ketamine When people are healed from depression, there is a lot of anxiety and activation that happens Infusion clinics don't offer the therapeutic help that comes with Ketamine Assisted Psychotherapy Benefits of Ketamine Psychotherapy The treatment method used at Polaris includes a comfortable room, eye shades, music tailored to the therapy, and an ongoing therapist They use non-ordinary states of consciousness as a part of the transformation They use lozenges and IM (Intramuscular) Only 30% of the ketamine from the lozenges are effective The lozenges allow for a slow onset of the medicine With IM, a higher dose can be used because it's less taxing on the body and more effective The property of Ketamine is dissociation Veronika says she prompts people to explain where they are, to share about what comes up for them “Sometimes there are memories that come up that are connected to their struggle. Sometimes they do full trauma processing. There are times where they go inside and then come out.” - Veronika Ketamine vs. Classic Psychedelics They used Ketamine as a means to do the work legally For the work that is being done underground, the therapists are putting themselves at risk for legality, and it does impact set and setting But even if other substances were legal, Veronika thinks Ketamine will still be used for certain issues Ketamine is described as a +4 on Shulgin’s scale A moderate to high dose can allow people to have a near death experience or ‘review of their life’ The dissociation that happens with Ketamine is a different dissociation that happens with trauma With trauma, dissociation happens when the nervous system can't handle the stress Opposingly, with Ketamine, it allows people who feel dissociated, to feel again Veronika mentions a study that says the higher the effects of dissociation from a Ketamine session, the higher the antidepressant effects are. She has work in somatic studies and organic intelligence Breathwork Veronika’s experience with Breathwork helps her understand her patients The bodily experience that happens in Breathwork also helps her understand the body movement/energetic blockages, etc that happen in Ketamine therapy The last 30-90 minutes is where the integration starts Sessions They do mainly one-on-one session but have done a few pair therapy sessions Veronika says its easier to do one-on-one because the sessions are short and there is a lot of internal work The Future of Ketamine Veronika is excited about people’s curiosity with Ketamine therapy and the effectivity of it Ketamine is a new and emerging field and we are figuring out who it is useful for and who it is not Veronika says that non-ordinary states are all beneficial for healing, and not having to use Ketamine (using Breathwork) is still beneficial “A big part of the healing is having a positive experience and connecting with places that feel good, having positive visions. Its supportive for our nervous system and our ability to heal.” - Veronika “When we allow the inner healing intelligence to come through, it will take us to where we need to go.” - Veronika Patients don't always need to just feel the dark stuff and the trauma, sometimes sitting with the good feelings and remembering what good feels like is a part of the healing too Kyle and Veronika were both on separate episodes of the Consciousness Podcast with Stuart Preston Podcast Episode 23 with Kyle Links Website Polaris About Veronika Gold Veronika has expertise in the treatment of trauma. Her approach is integrative and informed by Somatic Therapies, contemplative practices, and mindfulness. She also has an interest in educating others about the healing and transformational potential of non-ordinary states of consciousness.

How was MDMA invented? Who came up with the idea to add a methyl group to MDA, the "hug drug" of the 1960s?  Forget the irrelevant Merck patent of 1913. We found the person who "thought up" MDMA as a recreational drug. In 1975, on a hunch, Carl R. suggested to Sasha Shulgin that they methylate MDA. Later that Summer, they made a batch of MDMA together in a UC Berkeley laboratory, and Carl and his girlfriend were the first people on the planet (that we know of) to try it. This is part 2 of the secret history of MDMA, and this is the first time Carl tells his story to the world. Carl in 1975 Carl in 2018

This week we go deep in part two of my epic four-hour conversation with documentarian and gonzo journalist Charles Shaw – one of this show’s most requested return guests.In part one, Charles laid out the map of the problem: a world in crisis, an age of epidemic trauma and addiction. In this episode, we get into his self-experimentation with sleep deprivation to understand the hallucinatory reality of America’s homeless, his journey of healing and recovery working with entheogens and military veterans, and how facing and embracing our darkness with humility and courage may be the only way we can prepare ourselves to make a meaningful contribution to our world. Get ready for a heady brew of grit, dark humor, grief and relief, and the luminous truth that awaits us on the other side of suffering…Support these vital conversations with a small monthly contribution:http://patreon.com/michaelgarfieldSubscribe on Apple Podcasts • Stitcher • Spotify • iHeart RadioJoin our Facebook Discussion Group––––––––––––––––Part One:https://www.patreon.com/posts/16862172Charles on Youtube & Vimeo:https://www.youtube.com/user/UnheardVoicesArchivehttps://vimeo.com/nomadcinema“Meeting The Self You Aren’t,” excerpts from my talks with Charles on the 2010 Light & Shadow Tour:https://evolution.bandcamp.com/album/meeting-the-self-you-arentIn October and November 2010, I traveled to thirty cities across the United States with journalist and documentary film-maker Charles Shaw on what we called "The Light & Shadow Tour." Half our time was spent filming interviews for his documentary about the War on Drugs and prison industrial complex; half our time was spent engaging audiences in deep discussion on the role of what psychologists call "the shadow" in personal and cultural transformation. The shadow is the part of ourselves so profoundly disowned that it shows up not as a quality of the self, but a trait of other people - not a choice that we are making, but a fate that imposes itself upon us. And to whatever degree we continue to refuse acknowledgment of our shadows, we remain the desperate victims of life instead of its joyous collaborators. It isn't easy to write a new story of the self - and to constantly re-write that story, when new truths come to us in the form of disarming companions, rude awakenings, and other surprises. But it is the work set out before us, if we are to live as whole people and give the most of ourselves to the birthing of a new and better world.––––––––––––––––IN THIS EPISODE WE DISCUSS:- How seeking validation for his work made him miserable, but he moved through the crisis and the victimhood into a new sense of completeness;- How service to other people in the trauma and addiction healing process as an intake and integration facilitator at ibogaine clinics accelerated his own healing;- The puzzle of figuring out how to use psychedelics as part of the healing process for people with diagnosed mental disorders, for whom the action of psychedelics is still poorly understood;- The homelessness and drug addiction situation in San Francisco, a city in crisis and an “open-air asylum”;- How he took a personal journey into the insanity and delusional states of America’s growing homeless population through a gonzo journalist’s approach of firsthand speed use and sleep deprivation (up to nine days at a time, under clinical supervision);- What he learned from three years of intense work with entheogens about the experience of death and the emotional process of moving through epochal transitions;- Hanging out with the “shadow people,” the characteristic hallucinations that externalize our own repressed internal voices when we start to lose our minds;- Our resistance to treatment and medicine, because keeping things the way they are is easier, because healing is an ordeal that challenges our identities;- Getting to the heart of the inquiry of “Why am I doing what I’m doing, here?” and “What do I WANT?”- What it is to lose touch with the young and hungry, eager and determined artist that we used to be and then to find it in a painful retrospective, and to realize it was because we were out there seeking validation, hustling, instead of giving our lives to the work;- Is the conversation to identify the problem, or to critique by creating and move toward solutions?- How do we even TRY and turn the global conversation toward concerted action for positive and universal (planetoid) change?- We manage to sneak some Blade Runner 2049 in there…- Aging and growing older in our culture, which nobody wants to talk about;- A Luke Skywalker-esque critique of now-institutional festival culture;- The Pluto Transit (!!!);- Hungry Ghosts;- Going into the heart of darkness with veterans on ayahuasca and understanding what teamwork can do for psychedelic healing;- His dialogue with ayahuasca about visiting his late sister in the underworld, and how he found his peace with her passing;- Dodging the psychedelic messiah complex;- The astrology of Jesus and Piscean martyrdom;- How study of the archetypes inform our passage through the phases of our lives;- The truth about how being a prophet is a difficult, unappreciated act, not this glamorous role we imagine it to be;- How his film The Plastic People, on Tijuana and the deportation crisis, led to sweeping reforms in Mexico and pissed off countless Trump supporters on Netflix;- The challenges of documenting the secret history of the ibogaine underground;- The futility of protest in the postmodern information warfare landscape;- What Charles thinks was REALLY going on at Standing Rock, and how it’s related to the infiltration and disruption of the Women’s Movement;- How the government collects and processes intelligence on protesters and other political dissidents;- Can you have fun and still effect social change?- How learning the surprising hidden story of his own family changed how Charles thinks about identity and the human condition;- Big Mind Process and listening to the voice of “The Damaged Self”;- And more!––––––––––––––––CHARLES QUOTES:“I thought I was doing the right thing the whole time. I thought I was fighting the good fight. But at some point, you have to ask yourself why you keep ending up in the same situations.”“We are way too liberal with our use of the word ‘insane’ in our culture. Most of what people call insane is just plain suffering. End of story.”“Power is power for a reason. You want to take that shit on firsthand, you’re going to get hurt. A lot of young people don’t realize that.”“Healing’s an ordeal, and that’s the thing: most people check out too early. They actually make a decision on some level to just rather live their lives in dysfunction and unhappiness and keep repeating patterns and cycles rather than go through it, and go through the ordeal… Healing Land requires a stay in Shadow Land. If you want to heal, you gotta go through Shadow Land first.”[With homeless delusional behavior] “The drugs aren’t the problem, it’s the lack of sleep.”“Hoffman tested the acid, Shulgin tested the MDMA, I tested the insanity.”“Even Elon Musk cannot save the world, and frankly, I don’t think he’s a very palatable human being to begin with, but people love him and he’s kind of a sacred cow and you can’t criticism him, but I say ALL these billionaires are shifty and you can’t trust any of them.”“I’m not very good at killing myself. I should probably STOP.”“I don’t have to know how to do it right to know you are doing it wrong.”“Being a prophet means you’re never going to experience the things other people experience in life…it means you’re going to be alone and your whole existence is defined by your alienation from the status quo. But if you can accept it…”“Anybody who thinks there aren’t informants in the Native American community does NOT know the history of the Native American community.”“What is healing all about? So much of it is about accepting shit you can’t control.”“I’m not saying I’m better than anyone. I’m unique. I serve a unique function. And right now my unique function is to try to make the people that are the least understood in our culture more understood. I can do that. And I’ve sacrificed everything – my life, my body, a family, stability, everything – in pursuit of this, now across my fifth platform, the fifth group of despised subcultures. And I’m just going to keep going until we get to all of them. I may put the brakes on when we get to pedophiles – I’m not sure I can make an argument for that – but I study the people that do. Because it’s all about compassion. It is ALL about learning compassion.” See acast.com/privacy for privacy and opt-out information.

A conversation with Sylvia Thyssen, senior editor at the Erowid Center, about experience reports, drug geekery, Shulgin's notebooks, and Erowid's current Pineapple fund-matching drive.   

Here is the fifth edition of our monthly podcast series made by international artist. Featured this month : Hidden talent from Russia, Yuri Shulgin spreading the good vibes with this one hour selection traveling from jazz-funk to techno through Acid House and Deep gems. You'd better tune in... Follow us : www.facebook.com/MakeItDeep/?fref=ts Follow him :https://www.facebook.com/profile.php?id=1792666396

Download Neal M. Goldsmith, Ph.D. is a psychotherapist specializing in psychospiritual development. He is a popular speaker on drug policy reform, spiritual maturation, and the emergence of an integral society (a six-minute clip of his talk on the “Fusion of Spirit and Science” may be found at: http://vimeo.com/7517009) and an author, most recently of Psychedelic Healing: The Promise of Entheogens for Psychotherapy and Spiritual Development. Dr. Goldsmith has curated dozens of successful conferences and cross-disciplinary “meetings of minds” for corporations as well as the psychedelic community, including the Horizons and MAPS Psychedelic Science conferences. He is a founder of several discussion salons on integral philosophy, governance, media, postmodern science, healing, and the future of society. Trained in humanistic, transpersonal, and eastern traditions, Dr. Goldsmith maintains a (non-psychedelic) psychotherapy practice in New York and Sag Harbor, NY, and may be reached via his Web site: http://www.nealgoldsmith.com/psychedelics. Topics Discussed What Neal's practice looks like How Neal works with people who use psychedelics Self with a small "s" Aligning with one's Deeper self Creating health Sensory deprivation Maturity - long term vs short term Human history Use of sacred technology to align with long term good Psychedelic vs Psycholytic Approaches - Psychedelytic (combined) Maturation and rites of passage How do we transition to adulthood now? How one can become involved with the field Getting good grades, bringing good grants with you MAPS Erowid staff write ups Future research with adept Buddhist monks World religious leaders - research We have to be mature with this process. Comissions Meetings with leaders How to reintroduce back into society 279 chems from Shulgin to research - Chemical Modeling Autism research -UCLA - Alicia Danforth Influences Asagioli - Psychosynthesis Sándor Ferenczi - Love Oriented A.H. Almaas - Diamond Approach Allan Ajaya, Phd - Psychotherapy East and West: A Unifying Paradigm Stuart A. Kauffman - The Origins of Order: Self-Organization and Selection in Evolution Jonathan Ott - Pharmacotheon: Entheogenic Drugs, Their Plant Sources, and History Rupert Sheldrake - The Rebirth of Nature: The Greening of Science and God Links Neal's website Neals's Book - Psychedelic Healing – The Promise of Entheogens for Psychotherapy and Spiritual Development Twitter https://vimeo.com/16260822

Guest speaker: Sasha Shulgin PROGRAM NOTES: Today’s podcast features a talk given by Sasha Shulgin in 1996. In many ways this is a perfect Shulgin talk for a podcast because he didn’t use any photos or the chalkboard to assist in his presentation. This talk is also one of Sasha’s best presentations as for not […]

House, Tech House, Techno Tracklist Miles Dyson, Aaren San Feat BBK - Haze (Shulgin Remix) Wood Holly, Sage Armstrong - Ass Out (Original Mix) Sonny Fodera - Shake (Original Mix) Solardo - Dance The Disco (Original Mix) Prok & Fitch - Rhyme For Rhyme (Original Mix) Mendo - Dont Hold Back (Chus & Ceballos Remix) Dj Le Roi - I Get Deep (Late Night Tuff Guy Remix) Sonny Fodera, Mistic Bill - Invisible (U Won't C Me) (ITH Edit) Low Steppa - About Time feat Elisabeth Troy Mark Knight, Prok & Fitch - Into My Life (Original Mix) Filterheadz - Curve (Original Mix) Ant Brooks - Susan (Original mix) Dj Boris - Can You Hear Me (Enrico Saugiuliano Remix) Alan Fitzpatrick - Love Siren (Original Mix)

Dr. Sasha Shulgin's passing is celebrated in this talk by Dr. Bruce about a possible future global group overmind made possible in the 2040s by a 'Shulgin Chip'.

Dr. Sasha Shulgin's passing is celebrated in this talk by Dr. Bruce about a possible future global group overmind made possible in the 2040s by a 'Shulgin Chip'.

Guest speaker: Friends of Ann & Sasha Shulgin PROGRAM NOTES: On August 2, 2014, a memorial was held for Sasha Shulgin. In addition to several of the talks that were presented that afternoon, Bruce Damer captured a few sound bites from those in attendance. At the end of the podcast you will also hear a short segment from one of the famous “Ask the Shulgins” conversations. Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option Pihkal: A Chemical Love Story By Alexander Shulgin, Ann Shulgin Tihkal: The Continuation By Alexander Shulgin, Ann Shulgin The Shulgin Memorial (video) Shulgin on Alchemy, Basel, 2006

The passing of chemist Dr. Alexander 'Sasha' Shulgin, a.k.a. the Godfather of Psychedelics, inspired a discussion on MDMA. Dr. Shuglin perfected MDMA in the 1970s and authored two books about his psychedelic discoveries like 2C-B and DOM. Pauly reminds us about Dr. Shulgin's philosophy on self-experimentation and his message about psychedelics: "Use them with care." Shane and Pauly warn listeners about the wave of severe depression that accompanies heavy usage of MDMA. Shane reveals an affinity for chocolate and Pauly delves into his recent addiction to Two Dots. Shane sounds off the new 'Reefer Madness' in the media and Maureen Dowd's op-ed in NY Times about overdosing on cannabis edibles. Dope Media picks include Finding the Funk documentary, VICE interview with Dr. Sasha Shulgin, and Believer article on the future of marijuana growers in NoCal's Emerald Triangle.

Hosts Jake Kettle and James Kent talk about the death of Alexander Shulgin, the Shulgin Research Foundation, and James' recent visit to the Shulgin farm. To support the Shulgin family please visit ShulginResearch.org

Guest speaker: Paul Daley PROGRAM NOTES: Today's podcast features the 2013 Palenque Norte Lecture by Dr. Paul Daley in which he talks about Sasha Shulgin, his life and his work. Paul is one of the key people who has stepped in to consolidate and continue the experimental research begun by Dr. Shulgin. In addition to telling about Sasha's chemical research, Dr. Daley also talks about some of the reasons Sasha has given for why he does what he does. And we also hear about some of the ongoing research taking place in Sasha's laboratory, including research into a possible remedy for cluster headaches. Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option

Guest speaker: Sasha Shulgin Ways to help the Shulgins For non-tax-deductible contributions, Paypal $ to [annandsashashulgin@comcast.net] or snailmail: Sasha Shulgin, c/o Transform Press, PO Box 13675, Berkeley CA 94712. For tax-deductible online donations to support the completion of Shulgin publishing projects that are underway: http://www.erowid.org/donations/project_shulgin.php Please spread this information. Read the story of a member of our community who needs your help PROGRAM NOTES: In his next to last talk at the legendary Entheobotany Conferences in Palenque, Mexico, Sasha Shulgin holds forth on a host of topics ranging from his experiences in the navy during World War II, to how he first developed an interest in psychedelic chemistry, and on to a description of the processes and protocols he uses to develop new psychoactive compounds. The talk was given in January 2001. Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option

Experiential journalist Rak Razam interviews Hal Lucius, High Priest of consciousness with the Temple of Awakening Divinity, a travelling medicine space using 5-MEO-DMT as its active psychedelic eucharist. Lucius draws upon his past as a ceremonial magician in the Crowley/ Golden Dawn Alchemical Hermetic tradition to anchor this syncretic entheogenic church turning on the West Coast with a "complete dissolution of egoic consciousness". The Church claims a 95% success rate inducing a +4 on the Shulgin state with returning parishioners going into the godspace each time. But what are the dangers and logistics of a mystical-religious experience outsourced to an external catalyst? What are the benefits? Lucius posits that by changing the individual, the collective changes as well, and that the collective awakening is then part of the quickening of the paradigm change we are now experiencing. Is this the next wave of entheo-based gnostic religion? Hallaleuh, brothers and sisters! This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.

Please help the Shulgin's! Guest speakers: Timothy Leary and Ram Das PROGRAM NOTES: This is an audio collage of three talks. The first is by Dr. Leary in 1966. That is followed by a 1973 interview with Ram Das on his current feelings about Leary. The final segment is a 1986 appearance by Dr. Timothy Leary on the Larry King show. [NOTE: The following quotations are by Dr. Timothy Leary.] "Psychedelic art is the public face, a communication device, of our new religion." "Psychedelic drugs, which include marijuana, should be totally supervised by the state. That is, quality should be established, and you should have to be trained in how to use them, and they should be prescribed, and if you screwed up they'll take your license away. You'd have to show that you knew how to use them like [you do] an automobile." "I would say 90% of the kids who are under the age of 40 who are in computers now, ninety percent of them, have had some kind of experience in brain-change, or neurotransmission. That's why I may be misunderstood or not liked among certain segments of the country. But computer people really understand where I'm coming from and they welcome me." "The only defense against totalitarianism has always been, Jefferson said it too, constant vigilance on the part of the individual. There ain't no one going to protect us against Big Brother and Big Sister except ourselves linked up as free agents." "So go over there [India]. Try it all. Don't get hooked. Don't follow leaders. Watch your parkin' meters, and stay away from gurus. But try it all out!" "The basic trajectory of my life, no matter whether you agree with me (you don't have to agree with this) is to free yourself, to think for yourself, to question authority." "I love institutions. They're intelligence tests. Institutions are prisons that you have to escape from. . . . The only thing is don't get trapped in them. The most addictive, dangerous, mind-screwing thing in the world is conformity to an organization." Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option Eldridge Cleaver denouncing Timothy Leary in 1971 Listen Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option Eldridge Cleaver's friendly private message to Timothy Leary in 1995 Listen Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option Khadoma & Kevin: Deer Harbor Live -- Autumn 2010 Axis Mundi's Online YouTube Channel

Special one hour and forty minute edition of Media Roots Radio- Robbie and Abby Martin talk about the initiation and evolution of psychedelic drugs into our culture: the research, CIA experimentation & MKULTRA, the takeover and demonization of psychedelics following the 60s, MDMA and its use in psychology, the nature of consciousness, DMT and Lucid Dreaming. Following the broadcast are two songs from the new compilation being released by http://www.RecordLabelRecords.org The above timeline is interactive. Scroll through it to find out more about the show's music and to resources mentioned during the broadcast. This radio show airs on shortwave radio Sundays at 6pm central time, following the Alex Jones show. The frequency is 9.350 MHz. For more information go to http://www.MediaRoots.org

At the MAPS Psychedelic Science Conference 2010 with experiential journalist Rak Razam: * In perhaps his last public interview, Sasha Shulgin shares his thoughts on the future of psychedelics and the repositioning of 'drugs' in culture; the thrill of the chase in exploring virginal molecular landscapes and bringing back chemical maps; rules for safe ingestion and active levels of compounds... and the revelation of the most potent drug there is... * Carolyn (Adams) Garcia, aka Mountain Girl tells of her time in the boys club of the Merry Pranksters, hanging with Neal Cassady and Ken Kesey, and the gender politics of being the only girl with a motorbike for a thousand miles around La Honda in the early 60s... From the Pranksters to the Grateful Dead, and her marriage to Jerry Garcia, Mountain Girl has always been an integral part of the hippie tribe. Here she reveals the lessons of the infamous Acid Tests, the failure of "group mind", and her advice for women entering the psychedelic scene... * Alex and Allison Grey talk about the entheogenic origins of art and the mystic state of religion; the spiritual renaissance catalyzed by entheogens and a hunger for the transcendent; shamanic art and anchoring energy into this realm; the mapping of hyperspace by a generation of new psychedelic artists, and COSM - the Chapel of Sacred Mirrors and the Grey's mission to create a permanent home for visionary art... Sasha Shulgin pic courtesy Pati Lyall Mountain Girl pic courtesy of Lianne Gillooly Ralph Metzner pic courtesy of the web psychedelic background courtesy of Tim Parish and The Journeybook This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.

Guest speakers: Sasha Shulgin and Alan Watts PROGRAM NOTES: [NOTE: The following quotations are by Sasha Shulgin.] "So I look upon these materials [psychedelics] as being catalytic, not productive, they do not DO what occurs. The allow YOU to express what is in you that you had not had the ability to get to and express yourself without the help of a material." "I find that still the human animal is the only one that is really effective in evaluating and comparing these various psychedelic materials." [In testing a new substance] "You go with great caution. Decide what is the amount is that would have no effect and take one thousandths of that amount." "How does the mind work? What kind of a probe can you make to look at the function of the mind? To me, it's going to be a psychedelic material, that has very little action in experimental animals, to look into actions in man that are not seen in experimental animals." [NOTE: The following quotations are by Alan Watts.] "Nature has mercifully arranged the principle of 'forgettery' as well as the principle of memory. ... And you begin again. You see, it doesn't matter in what form you begin. Whether you begin again as a human being, or as a fruit fly, butterfly, or a beetle, or a bird, it feels the same way that you feel now. So we're really all in the same place." "So the possibility, even the imagination that there could be such an experience [of the end of the world] in the back of our heads, is the background which gives intensity to the sense that we call feeling good, feeling that it's all right." Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option

Pharmauscas glossalize and tantalize in their quest for the divine spark. What are ”rec-chems”, the thousands of new wave chemical compounds catalogued by bio-chemist Alexander Shulgin and others? What pathways do these compounds open up, and what do these keys say about the architecture of consciousness itself? Are rec-chems a neurochemical language of the divine, a “Neurobet” spoken only by a new wave of psychonautical translinguists? Is better living through chemistry possible, and what potentials does it offer us individually and as a species? What new maps of hyperspace do rec-chems open up? If rec-chems were integrated by society at large, would we be medicated or augmented? What are the dangers? Are rec-chems catalysts to transhumanity? Panel discussion held at EntheoGenesis Australis 2009 moderated by Rak Razam, featuring speakers: Torsten, Martin Williams, Jeremy, Nano Brain, Julian Palmer. photo courtesy of Spiral Monk c 2009 This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.

Guest speaker: Sasha Shulgin PROGRAM NOTES: [NOTE: The two quotations below are by Sasha Shulgin.] "Internally, no one's an elder. Internally everyone's kinda around 35 or so." "The people at the industry said, ‘Gee, if you have that kind of imagination that you can look at a structure and guess at another structure that might be active, why don't you just do whatever you want to do.' And I did." Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option

Guest speakers: Robert Forte, Ann Shulgin, Sasha Shulgin PROGRAM NOTES: "I think it's extraordinarily important, again, the context of set and setting that we use these drugs in, if we're going to succeed in the Psychedelic Renaissance, is something that needs to be underlined again and again." –Robert Forte "I would say that, arguably, the oldest use of psychedelics in our Western culture, let's say, is the Eleusinian Mysteries, which were a psychedelic drug ceremony that occurred every year for 2,000 years in ancient Greece." –Robert Forte "Using appropriate scientific methodologies and naturalistic observations, [Timothy Leary] showed that psychedelic drugs were safe. He showed their clinical effectiveness. He showed their effects on enhancing creativity." –Robert Forte "Personally, I think my most keen friend amongst the various phenethylamines and alkaloids I've worked with and synthesized has been 2CB. To me, it's a vary favorable, warm, and very comfortable compound." –Sasha Shulgin [MDMA] is the most remarkable insight drug, and is a suburb tool for psychotherapy." –Ann Shulgin "Any drug, including MDMA, the most it can do is open up what's inside you already." –Ann Shulgin "When I have not had a good psychedelic trip for, let's say, six months, I begin to feel that I'm beginning to get out of balance. … I think that instead of regarding psychedelics as a drain on the system, frankly, they are my favorite vitamin. That's the effect they have on me." –Ann Shulgin "And for all I know there are three, or four, or seven lives going on that I don't remember either awake or asleep, but I feel consciousness is my living relationship with the world." –Sasha Shulgin "My belief is that when you get involved in a psychedelic experience you are in a communication with part of yourself that you've given up trying to communicate with or forgotten about communicating with. So it's not something that's imposed by a drug. It's something [that is already there and] the drug allows you to experience and to function with. So I look upon it as being a revealing thing from within myself, rather than a thing imposed upon myself by an external drug." –Sasha Shulgin Download MP3 PCs – Right click, select option Macs – Ctrl-Click, select option Horizons: Perspectives on Psychedelics (2008 Conference) Horizons Conference audio online at the Internet Archive The Center for Cognitive Liberty and Ethics “Ghosts I” from Nine Inch Nails The first 9 tracks from the Ghosts I-IV collection available as high-quality, DRM-free MP3s, including the complete PDF.